A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Sponsor: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Terminated
To redefine study population
Other terminated trials from InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
More terminations from InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
A PHASE2 clinical study on Hyperbilirubinemia, Neonatal, this trial is terminated or withdrawn. The trial is conducted by InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company and has accumulated 10 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Nov 2019 [monthly]
Terminated PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Barcelona, Spain , Bydgoszcz, Poland , Chernivtsi, Ukraine , Colton, United States , Greenville, United States , Honolulu, United States , Kiev, Ukraine , Lodz, Poland , Louisville, United States and 9 more locations